Atacicept met its Phase 3 proteinuria reduction endpoint, supporting optimism for Vera's accelerated FDA approval filing ...

Novartis’ $1.7 billion Regulus Therapeutics buyout last month came after a hard-fought battle in which the Swiss pharma and ...

Rouzbeh Haghighat was serving on the board of Chinook Therapeutics at the time of the Novartis acquisition and, according to the DOJ’s allegations, used confidential information to conduct insider ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

Researchers found that nearly 28% of hospitalized chronic liver disease patients with acute kidney injury had alcohol-related disorders, as did almost 60% with hepatorenal syndrome.

Final draft guidance from NICE has backed NHS use of Filspari (sparsentan) for primary immunoglobulin A nephropathy (IgAN), ...

The U.S. FDA approved 20 drugs for market in April, slightly down from 22 in March, 16 in February and 12 in January. This brings the total number of FDA approvals for the first four months of 2025 to ...

Shares of Travere Therapeutics (Nasdaq: TVTX) fell 15.8% to $21.15 in after-hours trading, as the company revealed that the US Food and Drug Administration (FDA) has accepted its supplemental New Drug ...

Dupixent (dupilumab) Interleukin-4 receptor alpha antagonist Treatment of patients aged 12 years and older with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment.